NOTCH3 and non-small cell lung carcinoma: These findings indicate that the anti-NSCLC activity of EVO is at least in part due to the inhibition of the NOTCH3 signaling pathway, suggesting that EVO is a promising candidate which can be developed as a preventive or therapeutic agent by targeting NOTCH3 signaling in NSCLC.